Bicara Therapeutics (BCAX) Cash & Equivalents (2023 - 2026)

Bicara Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $323.5 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 30.0% year-over-year to $323.5 million in Q1 2026; TTM through Mar 2026 was $323.5 million, a 30.0% decrease from a year earlier, with the FY2025 full-year figure at $96.7 million, down 80.26% from the prior year.
• Cash & Equivalents grew to $323.5 million in Q1 2026 per BCAX's latest filing, from $96.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $520.8 million in Q3 2024 and bottomed at $96.7 million in Q4 2025.
• The 4-year median for Cash & Equivalents is $380.0 million (2025), against an average of $341.4 million.
• Across the five-year window, Cash & Equivalents surged 112.51% in 2024 and sank 80.26% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $230.4 million in 2023, then soared by 112.51% to $489.7 million in 2024, then sank by 80.26% to $96.7 million in 2025, then surged by 234.55% to $323.5 million in 2026.
• Per Business Quant, the three latest BCAX Cash & Equivalents figures stand at $323.5 million (Q1 2026), $96.7 million (Q4 2025), and $171.7 million (Q3 2025).